References
1. Gaziano TA. Economic burden and the cist-effectiveness of treatment of cardiovascular disease in Africa. Heart. 2008;94(2):140-144.
2. World Health Organization 2009. Cardiovascular Diseases. http://www.who.int/mediacentre/factsheets/fs317/en/index.htmlhttp://www.who.int/cardiovasculardiseases/priorities/en/index.html. Accessed June 17, 2010.
3. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian Journal of Medical Research 2006;124:235.
4. Jellinger PS, Smith DA, Mehta AE, Ganda O et al; American Association of Clinical Endocrinologist’ guidelines for management of dyslipidemia and prevention of athersclrosis, Endocrine practice. 2012;18(suupl-1):712.
5. Leiberman M, Marks AD. Digestion and Transport of Dietary Lipids. In Marks Basic Medical Biochemistry- A clinical approach.3rd edition. Lippincott Williams & Wilkins 2009;593-604.
6. Rader DJ, Hobbs HH. Disorders of lipoprotein metabolism. In Fauci, Braunwald, Kasper, Harrisons Principle of Internal Medicine. 17th edition, New York, McGraw Hill 2008:2;2416-2429.
7. Enas EA. Why is there an epidemic of malingnant CAD in young Indians? Asian J Clin Cardio. 1998;1:43-59.
8. Bottham KM, Mayes PA. Lipid transport and storage. In Murray RK, Granner DK, Rodwell VW. Harper’s Illustrated Biochemistry. 27th edition. McGraw Hill 2006;217-229.104
9. Thomas Demant, KatjaSeeberg, Andrea Bedynek Dietrich Seidel. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis 2001; 157:325-339.
10. Kamstrup PR, Benn M, Hansen AT, Nordestgaard BG. Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in The General Population: The Copenhagen City Heart Study. Circulation 2008;117:176-184.
11. Scanu AM, Fless GM. Lipprotein (a) Heterogeneity and Biological Relevance. J. Clin. Invest. 1990;85: 1709-1715.
12. Jones GT, Rij AMV, Cole J, Williams MJ, Bateman Eh, Marcovina SM et al. Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease. Clinical Chemistry 2007:53(4): 679-685.
13. Enas EA. http://www.cadiresearch.-com/illustrated.htm. Accessed 2002.
14. Von Eckardstein A, Schulte H, Cullen P, et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am CollCardiol. 2001;37:434-439.
15. Hoogeveen RC, Gambhir JK, Gambhir DS, et al. Evaluation of Lp(a) and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res. 2001;42:631-638.
16. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-1409.
17. Enas EA, Mehta JL. Lipoprotein(a): An important risk factor in coronary artery disease. J Am CollCardiol. 1998;32:1132-1134.
18. Solymoss BC, Marcil M, Wesolowska E, et al. Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 1993;72:1215-1219.
19. Hopkins PN, Wu LL, Hunt SC, et al. Lipoprotein(a) interactions with lipid and non lipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:2783-2792.
20. Enas EA, Senthilkumar A, Mathai A. Statins in the prevention and treatment of coronary artery disease: closing the knowledge and treatment gap. Asian J Clin Card. 2002;5:8-45.
21. Enas EA, Garg A, Davidson MA, et al. Coronary heart disease and its risk factors in first-generation immigrant Asia Indians to United States of America. Indian Heart J. 1996;48:343-353.
22. Enas EA, Jacob S. Coronary artery disease in Indians in the USA. In: Sethi K, ed. Coronary artery disease in Indians-a global perspective. Mumbai: Cardiological Society of India, 1998:32-43.
23. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection , evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
24. Mora S, Rifai N, Burring JE, Ridker PM. Fasting compared with non fasting lipids and Apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-1001.
25. Bansal S, Burring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with non fasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309-316.
26. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non fasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA. 2007;298:299-308.
27. Ridker PM. Fasting versus non fasting triglycerides and prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem.2008;54:11-13.
28. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and non fasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins and cardiovascular risk prediction. Circulation. 2008;118:2047-56.
29. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: A cross-sectional study. Arch Intern Med. 2012;172(22):1707-10.
30. Mora S, Rifai N, Buring JE and Ridker PM. Fasting compared with non fasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118:993-1000.
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.131
